Canada one of the top 10 accruing countries globally Wednesday, January 22, 2020 MAC18 (POSITIVE): A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy has closed to accrual after successfully reaching the accrual goal. Thanks to all of the CCTG sites who participated, making Canada one of the top 10 accruing countries globally and responsible for a quarter of the North American patients enrolled on the trial. As of December 2019 the final international accruals were 518 patients (target: 500) with 29 enrolled patients from Canada. The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest that this is the case also in women with a hormone receptor-positive breast cancer. There is also no indication of increased risk for delivery complications or for the newborn. The aim of the study is to investigate if temporary interruption of endocrine therapy, with the goal to permit pregnancy, is associated with a higher risk of breast cancer recurrence.The study aims also to evaluate different specific indicators related to fertility, pregnancy and breast cancer biology in young women. For more information visit the CCTG MAC18 webpage.
